In the following years, upregulation of IFITM3 in tumor tissues in comparison with paratumor tissues was confirmed in multiple cancers, such as gastric cancer (44), breast cancer (45), prostate cancer (46), and lung cancer (47). This evidence concerns the gene IFITM3 and prostate cancer.